Richard D. Beger
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Branch Chief
Also affiliated: Wesleyan University (1995–1998); University of Hawaiʻi at Mānoa (2006); United States Department of Health and Human Services (2009); United States Food and Drug Administration (2000–2025); University of Hawaii System (2006); Center for Drug Evaluation and Research (2020); Suzuki (Japan) (2007); University of Wisconsin–Madison (1999); Johns Hopkins University (1993); Kangwon National University (2006–2007); Purdue University West Lafayette (1989–1992); Johns Hopkins Medicine (1993); Northrop Grumman (United States) (2004); Thomas Jefferson National Accelerator Facility (2012); National Institute of Environmental Health Sciences (2000); Division of Chemistry (2006); National Cerebral and Cardiovascular Center (2007); Centre for Alternative Technology (2018); Food and Drug Administration (2012–2021); Center for Systems Biology (2024); Obihiro University of Agriculture and Veterinary Medicine (2007); University of Pennsylvania (1999); University of Birmingham (2016); Kumamoto University (2007)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Richard D. Beger's research focuses on the application of advanced analytical techniques, particularly metabolomics and mass spectrometry, to address challenges in toxicology and regulatory science. His work involves developing and implementing quality assurance and quality control measures for untargeted metabolic phenotyping, contributing to standardized reporting frameworks for transcriptomics and metabolomics in regulatory toxicology, such as those developed by the OECD.
Beger has investigated the use of reference materials in metabolomics and lipidomics and explored emerging technologies impacting regulatory science. His publications also touch upon the translational potential of metabolomics for precision medicine and the discovery of proteomic biomarkers for conditions like acute kidney injury. He has a significant publication record with 218 publications and over 13,000 citations, and is recognized as a highly cited researcher. His collaborations are primarily within the National Center for Toxicological Research, including with Jinchun Sun, Lisa Pence, Amy L. Inselman, and Kellie A. Woodling.
Metrics
- h-index: 48
- Publications: 218
- Citations: 14,023
Selected Publications
-
Assessing the developmental effects of fentanyl and impacts on lipidomic profiling using neural stem cell models (2025)
-
Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop (2025)
-
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)
-
The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses (2024)
-
Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial (2024)
-
Identification of Proteomic Biomarkers of Acetaminophen-Induced Hepatotoxicity Using Stable Isotope Labeling (2024)
-
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model (2024)
-
Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples (2023)
-
Metabolomics evaluation of the photochemical impact of violet-blue light (405 nm) on ex vivo platelet concentrates (2023)
-
Prediction and Experimental Evaluation of the hERG Blocking Potentialof Drugs Showing Clinical Signs of Cardiotoxicity (2022)
-
Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management (2022)
-
Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs (2022)
-
Evaluating Cefoperazone-Induced Gut Metabolic Functional Changes in MR1-Deficient Mice (2022)
-
Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC) (2022)
-
Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy (2021)
Collaboration Network
Top Collaborators
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Metabolomics evaluation of the photochemical impact of violet-blue light (405 nm) on ex vivo platelet concentrates
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
Showing 5 of 6 shared publications
- Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Identification of Proteomic Biomarkers of Acetaminophen-Induced Hepatotoxicity Using Stable Isotope Labeling
- Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
- Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial
- Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
- Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Evaluating Cefoperazone-Induced Gut Metabolic Functional Changes in MR1-Deficient Mice
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Discovery of Novel Proteomic Biomarkers for the Prediction of Kidney Recovery from Dialysis-Dependent AKI Patients
- Serum metabolite profiles predict outcomes in critically ill patients receiving renal replacement therapy
- Identification of structural factors that affect binding to cannabinoid receptor type 1
- Prediction and Experimental Evaluation of the hERG Blocking Potentialof Drugs Showing Clinical Signs of Cardiotoxicity
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Analysis types and quantification methods applied in UHPLC-MS metabolomics research: a tutorial
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
- Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC)
- Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples
Similar Researchers
Based on overlapping research topics